Mucocutaneous Adverse Events Associated With Oral Sirolimus for the Treatment of Vascular Anomalies

Pierre-Olivier Grenier; Lindsay McCormack; Shomoukh A Alshamekh; Denise M Adams; Cameron C Trenor 3rd; Meghan J O'Hare; Marilyn G Liang

doi:10.1001/jamadermatol.2020.5180

Mucocutaneous Adverse Events Associated With Oral Sirolimus for the Treatment of Vascular Anomalies

JAMA Dermatol. 2021 Feb 1;157(2):233-235. doi: 10.1001/jamadermatol.2020.5180.

Authors

Pierre-Olivier Grenier^{1

2}, Lindsay McCormack^{1

3}, Shomoukh A Alshamekh^{1

2}, Denise M Adams^{2

4

5}, Cameron C Trenor 3rd^{2

4}, Meghan J O'Hare^{2

4}, Marilyn G Liang^{1

2}

Affiliations

¹ Department of Dermatology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
² Vascular Anomalies Center, Boston Children's Hospital, Boston, Massachusetts.
³ University of Massachusetts Medical School, Boston.
⁴ Boston Children's Hospital, Division of Hematology/Oncology, Harvard Medical School, Boston, Massachusetts.
⁵ Complex Vascular Anomalies Program, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Abstract

This case series examines the clinical spectrum and frequency of mucocutaneous adverse events related to oral sirolimus in populations with vascular anomalies.

MeSH terms

Administration, Oral
Adolescent
Adult
Child
Child, Preschool
Female
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / adverse effects*
Infant
Infant, Newborn
Male
Middle Aged
Mucous Membrane / drug effects*
Mucous Membrane / pathology
Retrospective Studies
Sirolimus / administration & dosage
Sirolimus / adverse effects*
Skin Diseases / chemically induced*
Skin Diseases / pathology
Vascular Malformations / drug therapy
Young Adult

Substances

Immunosuppressive Agents
Sirolimus